Feb 11 (Reuters) – Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials.

“We are exploring various device presentations for Wegovy, including vials – some are launching this year, others are coming in the future,” the company said.

Novo currently sells Wegovy in injectable and oral versions.

Rival Eli Lilly started selling vials of the two lowest doses of its popular weight-loss drug Zepbound in 2024.

Last year, Lilly cut the price for vials of Zepbound by $50 or more and expanded the range of doses sold online.

Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a bruising year in which Zepbound overtook Wegovy in U.S. prescriptions.

(Reporting by Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri)